Daily Stock Analysis, HALO, Halozyme Therapeutics Inc, priceseries

Halozyme Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
16.61
Close
16.52
High
16.85
Low
16.39
Previous Close
16.49
Daily Price Gain
0.03
YTD High
17.79
YTD High Date
Jul 3, 2019
YTD Low
13.84
YTD Low Date
Jan 3, 2019
YTD Price Change
1.72
YTD Gain
11.62%
52 Week High
18.76
52 Week High Date
Oct 3, 2018
52 Week Low
13.24
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-0.75
52 Week Gain
-4.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2017
10.69
Jan 11. 2017
12.07
5 Trading Days
12.92%
Link
LONG
Jun 16. 2017
13.44
Jun 27. 2017
14.17
7 Trading Days
5.42%
Link
LONG
Sep 13. 2017
13.18
Oct 6. 2017
17.17
17 Trading Days
30.31%
Link
LONG
Jan 4. 2019
14.72
Jan 23. 2019
15.83
12 Trading Days
7.55%
Link
Company Information
Stock Symbol
HALO
Exchange
NasdaqGS
Company URL
http://http://www.halozyme.com
Company Phone
(858) 794-8889
CEO
N/A
Headquarters
California
Business Address
11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121-1345
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001159036
About

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other d...

Description

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.